Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ORGANIZATION
ORGANIZATION
- 70% of Younger Wholesaler Staffers Ponder Quitting Jobs amid Supply Crunch: Poll
October 30, 2023
- Shipments Curbed or Suspended for 22.9% of Products in September: FPMAJ
October 27, 2023
- Japan Needs New Rule to Price Drugs on Par with US, Europe: JPMA Director
October 27, 2023
- JMA to Seek Wage Hike of “at Least 3%” in 2024 Revision: President
October 27, 2023
- Chuikyo Rep Interview 3-2 - Rengo Wants Substantive Discussions on Pricing System, Off-Year Revisions over Next Few Years
October 26, 2023
- Off-Label Use of GLP-1 Goes against Medical Ethics: JMA Executive
October 26, 2023
- Chuikyo Rep Interview 3-1 - Rengo Seeks Patient-Centric Debate, Sees Exhausted Wholesalers as Big Issue
October 25, 2023
- Neurology Society, SMA Group Urge Nationwide Newborn Test at Public Expense
October 20, 2023
- No Info Received from Member Firms on Impact of Middle East Crisis: JPMA
October 20, 2023
- JGA Vows Cooperation after Generic Panel’s Interim Report
October 20, 2023
- JPMA Renews Call for Abolishing PMP Company Criteria
October 20, 2023
- Group of Academia-Originating Biotechs Boots Up in Japan
October 18, 2023
- Introduce Societal Value Premium for Regenerative Medicine Products: Consultant
October 17, 2023
- Chuikyo Rep Interview 2-3 - With 80% Generic Share, Now Is the Time to Revisit LLP Copay, Says Payer Rep
October 13, 2023
- Chuikyo Rep Interview 2-2 - Payer Says Drug Prices Not Only Cause of Lag/Loss, Industry Proposal Needs More Details
October 11, 2023
- JMA Survey Finds Large Gap between Actual Drug Shortage, Industry Poll
October 11, 2023
- Chuikyo Rep Interview 2-1 - As Japan Sees More Pricey Meds, Kenporen Director Wants Rethink of Health Coverage
October 10, 2023
- Eliminate Authorized Generics as They Hamper Competition: JMA
October 10, 2023
- Global CEOs Want Positive Sign from Japan, Sentiments Drive Decisions: EFPIA Chief
October 6, 2023
- Chuikyo Rep Interview 1 - JPA Vice President Warns against Rushed Dabate on Yakkasa, 2% Buffer Zone
October 4, 2023
ページ
Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…